If Eli Lilly Grows At 10% a Year, Here’s What $1,000 Becomes By 2030
Eli Lilly just posted 47.7% revenue growth and its weight-loss drugs are reshaping global healthcare, but whether that momentum turns a four-year investment into a windfall or a disappointment depends on factors most investors overlook.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo